...
首页> 外文期刊>British journal of ophthalmology >Current therapeutic developments in atrophic age-related macular degeneration
【24h】

Current therapeutic developments in atrophic age-related macular degeneration

机译:萎缩性年龄相关性黄斑变性的当前治疗进展

获取原文
获取原文并翻译 | 示例
           

摘要

Age-related macular degeneration (AMD), a degenerative disorder of the central retina, is the leading cause of irreversible blindness in the elderly. The underlying mechanism of the advanced form of dry AMD, also named geographic atrophy (GA) or atrophic AMD, remains unclear. Consequently, no cure is available for dry AMD or GA. The only prevention option currently available is the Age-Related Eye Disease Study (AREDS) formulation, which has been demonstrated to slow down the progression of dry AMD. This review summarises recent advances in therapy for dry AMD and GA. Building on the new understanding of the disease and recent technological breakthroughs, numerous ongoing clinical trials have the goal of meeting the need to cure AMD. Therapeutic agents are being developed to target the key features of the disease, including inhibiting the complement pathway and other inflammatory pathways, reducing oxidative stress and protecting retinal pigment epithelial (RPE) cells, inhibiting lipofuscin and visual cycle, regenerating RPE cells from stem cells and restoring choroidal blood flow. Some of these therapeutic options, especially the stem cell-based therapy, hold great promise, which brings great hope for this devastating blinding disease.
机译:与年龄有关的黄斑变性(AMD)是中央视网膜的变性疾病,是老年人不可逆转失明的主要原因。干性AMD先进形式(也称为地理萎缩(GA)或萎缩性AMD)的潜在机制尚不清楚。因此,没有治疗方法可用于干燥的AMD或GA。当前唯一可用的预防选择是与年龄有关的眼疾研究(AREDS)制剂,该制剂已被证明可以减慢干燥AMD的进程。这篇综述总结了干燥AMD和GA治疗的最新进展。基于对疾病的新认识和最近的技术突破,许多正在进行的临床试验的目标是满足治愈AMD的需求。正在开发针对该疾病关键特征的治疗剂,包括抑制补体途径和其他炎性途径,减少氧化应激并保护视网膜色素上皮(RPE)细胞,抑制脂褐素和视觉周期,从干细胞和恢复脉络膜血流。这些治疗选择中的一些,尤其是基于干细胞的治疗,具有广阔的前景,这为这种毁灭性致盲性疾病带来了巨大希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号